Skip to main content
Vicore Pharma Holding logo

Vicore Pharma Holding — Investor Relations & Filings

Ticker · VICO ISIN · SE0007577895 LEI · 549300KTNBPTZLF01130 ST Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2024-02-09 Regulatory Filings
Country SE Sweden
Listing ST VICO

About Vicore Pharma Holding

https://vicorepharma.com/

Vicore Pharma Holding is a clinical-stage pharmaceutical company developing a new class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), with disease-modifying potential. The company's research focuses on diseases where the AT2 receptor has a central role in stopping and reversing pathology. Its lead candidate, buloxibutid (C21), is a first-in-class, orally available small molecule ATRAG in clinical development for idiopathic pulmonary fibrosis (IPF). Vicore is also developing Almee™, a digital therapeutic based on cognitive behavioral therapy for the psychological impact of pulmonary fibrosis, which has received FDA Breakthrough Device Designation. The company utilizes its expertise in ATRAG chemistry and biology to build a pipeline primarily focused on respiratory diseases.

Recent filings

Filing Released Lang Actions
Vicore och Nippon Shinyaku ingår exklusivt licensavtal för utveckling och kommersialisering av C21 i Japan
Regulatory Filings Classification · 98% confidence The document is a press release dated February 9, 2024, announcing an exclusive licensing agreement between Vicore Pharma and Nippon Shinyaku for the development and commercialization of drug candidate C21 in Japan. It details financial terms (upfront payment, milestones, royalties) and strategic implications. The text concludes with a statement indicating that the information is 'such information that Vicore Pharma Holding is obliged to make public according to the EU Market Abuse Regulation' and specifies the release time. This structure strongly suggests a formal regulatory announcement intended for immediate public disclosure, rather than a comprehensive financial report (like 10-K or IR) or a simple presentation (IP). Since it is a general regulatory announcement that doesn't fit perfectly into specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate classification is the general regulatory filing category, RNS (Regulatory News Service/Announcements). The document length (5818 chars) is substantial enough to be the announcement itself, not just a brief notice pointing to an attachment.
2024-02-09 Swedish
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
Regulatory Filings Classification · 95% confidence The document announces an exclusive licensing agreement between Vicore Pharma and Nippon Shinyaku regarding the drug candidate C21 for the Japanese market. This involves a significant financial transaction (upfront payment, milestones, royalties) and grants exclusive rights for development and commercialization. This type of corporate action, specifically related to fundraising, financing activities, or capital structure changes (in this case, licensing intellectual property for future revenue streams), aligns best with the 'Capital/Financing Update' category. Although it is a press release, the core subject matter is a major financing/licensing deal, making 'CAP' more specific than a general 'RNS'. The document is a full announcement, not just a notice that a report is attached, so RPA/RNS is less appropriate than CAP.
2024-02-09 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vicore Pharma Holding AB for the period of July 1 to September 30, 2023. It contains comprehensive financial statements, management commentary, notes, and an auditor's review report. It is not an announcement of a report, but the report itself, containing substantive financial data. 9M 2023
2023-11-02 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'Interim report Jul 1-Sep 30, 2023' and 'Interim report Q3 2023'. It contains comprehensive financial statements, including a summary of the period, financial overview, group financial summary, and detailed breakdowns of operating income and expenses. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2023
2023-11-02 English
Vicore announces the Nomination Committee for the 2024 Annual General Meeting
Board/Management Information Classification · 99% confidence The document explicitly announces the appointment of the Nomination Committee for the upcoming 2024 Annual General Meeting (AGM). It details the committee members, their appointing shareholders, and the tasks associated with preparing for the AGM (e.g., board elections, fees). This content is directly related to the preparation and governance surrounding the Annual General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R). Although it mentions the AGM, it is not the proxy statement (DEF 14A/PSI) or the voting results (DVA), but rather preparatory information for the meeting.
2023-10-31 English
Vicore offentliggör valberedningen inför årsstämman 2024
Board/Management Information Classification · 99% confidence The document is a press release from Vicore Pharma Holding AB announcing the composition of the Nomination Committee (Valberedningen) for the upcoming Annual General Meeting (Årsstämman) in 2024. It details who has been appointed to the committee by major shareholders and outlines the committee's tasks regarding board nominations and remuneration. This type of announcement, concerning the preparation for the AGM, specifically relates to the governance and procedural aspects leading up to the meeting. While it is related to the AGM, it is not the AGM presentation itself (AGM-R) or the proxy materials (DEF 14A/PSI). It is a specific corporate governance announcement regarding the nomination process. Given the options, this announcement about the composition and process for the AGM nomination committee is best classified as a general corporate governance/regulatory announcement. Since it is a specific announcement about the structure leading to the AGM, and not the AGM materials themselves, and it doesn't fit perfectly into other specific categories like Director's Dealing or Capital Changes, it falls under the general regulatory/governance disclosure umbrella. However, since the content is entirely focused on the nomination committee for the AGM, and the AGM is a key event, we must check if there is a better fit. The closest related items are AGM-R (the meeting materials) or DEF 14A (Remuneration/Proxy). Since this is about *nominations* for the board, it is a key governance step. Given the available codes, and recognizing this is a formal announcement about the governance structure preceding the AGM, it is most closely related to general corporate governance disclosures. If we consider the context of the AGM preparation, it is a specific procedural announcement. Since it is not a DEF 14A (which focuses on remuneration/proxy voting details) or AGM-R (the meeting presentation), and it is a formal regulatory disclosure, the most appropriate general category for a specific governance announcement that isn't explicitly covered is RNS (Regulatory Filings) or potentially CGR (Governance Information). Because the core subject is the nomination committee structure for the AGM, which is a fundamental governance function, CGR is a strong candidate. However, RNS is the fallback for specific regulatory announcements. Given the focus on the 'Valberedning' (Nomination Committee), which is a key part of corporate governance, CGR is a better fit than the general RNS fallback, as it details internal rules/structure preparation. The document length is short (3461 chars) and it is a press release announcing the formation of a committee whose proposals will be presented later, fitting the pattern of an announcement rather than a full report. I will classify it as CGR as it directly concerns the governance structure preparation for the AGM.
2023-10-31 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.